[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585003":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":25,"locations":29,"responsibleParty":102,"collaborators":25,"id":106,"slug":25,"hasResults":107,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":107,"sex":113,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":25,"studyType":119,"phases":120,"briefSummary":122,"conditions":123,"keywords":25,"overallStatus":63,"whyStopped":25,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},{"fullName":5,"class":6},"Guangdong Provincial People's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intensive lipid-lowering strategy","EXPERIMENTAL","LDL-C reduce to \\\u003C1.0mmol\u002FL and by ≥50% relative to baseline levels.",[13],"Drug: Intensive lipid-lowering strategy",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard lipid-lowering strategy","ACTIVE_COMPARATOR","LDL-C reduce to \\\u003C1.8mmol\u002FL and by ≥50% relative to baseline levels.",[19],"Drug: Standard lipid-lowering strategy",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","The initial recommended therapy is 20mg atorvastatin\u002F10mg rosuvastatin plus Ezetimibe or PCSK9i, and the type and dosage of drugs can be adjusted according to the situation. If the target LDL-C level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"The initial recommended therapy is 20mg atorvastatin\u002F10mg rosuvastatin, and the type and dosage of drugs can be adjusted according to the situation. If the target L-DLC level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.",[15],[30,43,53,62,74,83,92],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":25},"The First Affiliated Hospital of Chongqing Medical University","NOT_YET_RECRUITING","Chongqing","Chongqing Municipality","400015","China",{"type":38,"coordinates":39},"Point",[40,41],106.55771,29.56026,{"lat":41,"lon":40},{"facility":44,"status":32,"city":45,"state":46,"zip":47,"country":36,"cosmosGeoPoint":48,"geoPoint":52,"contacts":25},"The Ninth Clinical Medical College of Guangzhou University of Chinese Medicine","Dongguan","Guangdong","523000",{"type":38,"coordinates":49},[50,51],113.74866,23.01797,{"lat":51,"lon":50},{"facility":54,"status":32,"city":55,"state":46,"zip":56,"country":36,"cosmosGeoPoint":57,"geoPoint":61,"contacts":25},"The Third Affiliated Hospital of Guangzhou Medical University","Guangzhou","510000",{"type":38,"coordinates":58},[59,60],113.25,23.11667,{"lat":60,"lon":59},{"facility":5,"status":63,"city":55,"state":46,"zip":64,"country":36,"cosmosGeoPoint":65,"geoPoint":67,"contacts":68},"RECRUITING","510100",{"type":38,"coordinates":66},[59,60],{"lat":60,"lon":59},[69],{"name":70,"role":71,"phone":72,"phoneExt":25,"email":73},"Yong Liu, MD, PhD","CONTACT","+86 2083827812","liuyong@gdph.org.cn",{"facility":75,"status":32,"city":76,"state":46,"zip":77,"country":36,"cosmosGeoPoint":78,"geoPoint":82,"contacts":25},"The Eighth Affiliated Hospital of Sun Yat-sen University","Shenzhen","518033",{"type":38,"coordinates":79},[80,81],114.0683,22.54554,{"lat":81,"lon":80},{"facility":84,"status":32,"city":85,"state":46,"zip":86,"country":36,"cosmosGeoPoint":87,"geoPoint":91,"contacts":25},"Zhongshan People's Hospital","Zhongshan","528400",{"type":38,"coordinates":88},[89,90],113.37912,22.52306,{"lat":90,"lon":89},{"facility":93,"status":32,"city":94,"state":95,"zip":96,"country":36,"cosmosGeoPoint":97,"geoPoint":101,"contacts":25},"The First Affiliated Hospital of Dalian Medical University","Dalian","Liaoning","116000",{"type":38,"coordinates":98},[99,100],121.60222,38.91222,{"lat":100,"lon":99},{"type":103,"investigatorFullName":104,"investigatorTitle":105,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Liu yong","MD","100585003",false,"NCT06896708","Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome","Coronary Computed Tomography Study to Assess the Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome: A Nationwide, Multicentre, Randomized Controlled Trial","CAPITAL-PLAQUE","Inclusion Criteria:\n\n1\\. Aged 18-60 years at screening 2. Stable angina symptoms with suspected or confirmed coronary artery disease; 2. CCTA examination demonstrating: at least one major coronary artery with a diameter of ≥1.5mm that has not been intervened and at least one leision with 50%-70% stenosis.\n\n3\\. Subjects who have been using statin therapy alone for at least 4 weeks prior to enrollment with a baseline LDL-C ≥1.8mmol\u002FL or subjects who have not initiated lipid-lowering therapy prior to enrollment with a baseline LDL-C≥2.6mmol\u002FL.\n\nExclusion Criteria:\n\n1. Left main coronary artery disease or severe three-vessel disease;\n2. Ultra-high-risk ASCVD patients: ≥2 severe ASCVD events or 1 severe ASCVD event with ≥2 high-risk factors;\n3. Use of PCSK9 inhibitors or ezetimibe within 8 weeks prior to study enrollment;\n4. The baseline LDL-C was relatively high (LDL-C≥2.6 mmol\u002FL in those taking statins and ≥4.9 mmol\u002FL in those not taking statins).\n5. Familial hypercholesterolemia;\n6. Known allergy\u002Fintolerance to lipid-lowering drugs used in the trial;\n7. Patients with severe congestive heart failure, liver or kidney dysfunction, or malignancy;\n8. Pregnant or breastfeeding female patients.","ALL","18 Years","60 Years",{"count":117,"type":118},766,"ESTIMATED","INTERVENTIONAL",[121],"NA","This is a multicenter, open-label, parallel-group, randomized trial to determine if intensive lipid-lowering therapy (goal for LDL-C \\\u003C1.0 mmol\u002FL and ≥50% reduction frome baseline) could delay progression of coronary atherosclerotic obstructive leisions compared with guideline recommended lipid-lowering therapy (goal for LDL-C \\\u003C1.8 mmol\u002FL and ≥50% reduction frome baseline) among participants between 18-60 years old with non-invasively managed chronic coronary syndrome (at least one lesion with a 50%-70% stenosis).",[124],"Chronic Coronary Syndrome","2025-12-09",{"date":127,"type":128},"2025-12-17","ACTUAL",{"date":130,"type":128},"2025-08-12",{"date":132,"type":118},"2028-03-01",{"name":104,"class":6},7]